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Abstract (224 words) 
 
Background: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in 
sarcoidosis. We established a multi-national registry of sarcoidosis associated PH (SAPH) patients. 
Methods: Sarcoidosis patients with PH confirmed by right heart catheterization (RHC) were studied. 
Patients with pulmonary artery wedge pressure(PAWP) of 15 mmHg or less and a mean pulmonary 
artery pressure (mPAP) > 25 Hg were subsequently analyzed. Data collected included hemodynamics, 
forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO), chest x-ray, and six-minute 
walk distance (6MWD). 
Results: A total of 176 patients were analyzed. This included 84 (48%) cases identified within a year of 
entry into the registry and 94 (53%) with moderate to severe PH. There was a significant correlation 
between DLCO percent predicted (% pred) andmPAP (Rho=-0.228, p=0.0068) and pulmonary vascular 
resistance (PVR) (Rho=-0.362, p<0.0001).  PVR was significantly higher in stage 4 disease than in stage 0 
or 1 disease (p<0.05 for both comparisons). About two-thirds of the SAPH patients came from the 
United States (US). There was a significant difference in the rate of treatment between US (67.5%) 
versus non-US (86%) (Chi Square 11.26, p=0.0008) sites.  
Conclusions The clinical features of SAPH were similar across multiple centers in the US, Europe, and the 
Middle East. The severity of SAPH was related to reduced DLCO. There were treatment differences 
between the US and non-US centers.   
Key words: sarcoidosis associated pulmonary hypertension, epidemiology, sarcoidosis 
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Introduction 
 
Sarcoidosis associated pulmonary hypertension (SAPH) is associated with significant morbidity and an 
increased mortality 
1-4
.  The incidence of SAPH in a general sarcoidosis clinic varies between 5 to 20% 
5-7
. 
The lower rates have been reported in general sarcoidosis clinics 
5
, while higher rates have been 
reported from tertiary referral clinics 
6
. Over half of sarcoidosis patients with persistent dyspnea or 
listed for lung transplant have SAPH 
1;8;9
. Despite increased recognition of SAPH over the past decade, 
there are still significant gaps in knowledge about this condition and there are no direct comparisons 
between the features or treatment of SAPH in various parts of the world. 
 
To gather more knowledge about the disease, we established an observational Registry for Sarcoidosis 
Associated Pulmonary Hypertension (ReSAPH) to prospectively collect data on patients with incident or 
prevalent SAPH.  The registry was designed to collect information regarding the initial presentation and 
subsequent clinical course of SAPH patients from sarcoidosis centers across the world.  Data collected 
included hemodynamic measures to assess severity of pulmonary hypertension, pulmonary function 
testing and chest imaging to characterize the underlying pulmonary involvement, and six-minute walk 
distance (6MWD).  We also collected information on treatment for the pulmonary hypertension. We 
now report the analysis of the demographics, disease course, and management of the first 176 patients 
with pre-capillary SAPH and compare those results to pulmonary sarcoidosis patients without 
pulmonary hypertension. We also compared the clinical features of SAPH for United States (US) and 
non-US sites. 
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Materials and Methods 
 
Patients with a diagnosis of sarcoidosis based on the ATS/ERS/WASOG criteria and hemodynamic 
diagnosis of PH were enrolled in an eleven center observational registry 
10
. The registry was initiated in 
October 2011. All patients were required to have at least one right heart catheterization (RHC) 
demonstrating a mean pulmonary artery pressure (mPAP) ≥25 mmHg. Incident cases were defined as 
the diagnosis of PH within one year of entry into the registry, whereas prevalent cases were diagnosed 
more than a year prior. Patients were recruited from individual clinic patients. There was no advertising 
or other efforts to recruit all SAPH patients within each geographic area of the individual clinic. The 
overall study was designed to recruit 200 patients with half of cases to be incident cases. This sample 
size was based on prior single center studies of SAPH patients. All information was recorded in a secure 
web- based electronic database (REDCap) 
11
. Each investigator had obtained local institutional review 
board approval prior to entering any patient into the database. The study is registered at ClinTrials.gov 
at number NCT01467791. The authors used the STROBE (Strengthening The Reporting of Observational 
Studies in Epidemiology) checklist in preparing this report. 
 
For each patient, the first RHC identifying PH was recorded. Values recorded included the mean right 
atrial (RA) pressure, systolic, diastolic, and mPAP, the pulmonary artery wedge pressure (PAWP), cardiac 
output (CO) by thermodilution, and cardiac index (CI). Pulmonary vascular resistance (PVR) was 
calculated and reported in Wood units.  
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At time of entry into the study, all patients underwent a history and focused physical examinations.  
Age, gender, self-declared race, organ involvement using standard criteria 
12;13
, duration of sarcoidosis 
and SAPH were recorded. Pulmonary function studies data obtained included forced vital capacity (FVC), 
forced expiratory volume in one second (FEV1), the ratio of FEV1 to FVC, (FEV1/FVC) and diffusion 
capacity of carbon monoxide (DLCO) with % predicted values using the local laboratory formulas 
correcting for race and hemoglobin. PH-specific therapy was recorded. When available, the most recent 
chest x-ray at the time of entry into the study was reviewed and staged using Scadding criteria 
14
.  
 
For the US sites and one site in Europe (Rotterdam), additional information was obtained on all patients 
enrolled.  Information collected included 6MWD using a standard protocol 15,16, oxygen saturation and 
Borg score 
15
 initially and at the end of walking, as well as the use and rate of supplemental oxygen 
during the test. 
 
 
Statistics 
Correlations between variables were calculated using Spearman rank correlation using MedCalc 
Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 
2014). Kruskal Wallis testing was performed to analyze for variance between groups. Chi square was 
performed to compare factors. Comparison between groups were made using Mann Whitney U test. A p 
value of less than 0.05 was considered significant.  
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Results 
 
At the time of this analysis in May 2017, 216 patients were enrolled. Supplement Table 1 lists the sites, 
principal investigator at each site, and number of patients enrolled. Seven of the eleven sites (five from 
US and two non US) enrolled 19 or more patients. The hemodynamic data of all these patients was 
reviewed and 176 patients with documented mPAP≥25 mm Hg and a PAWP of ≤15 mmHg  constituted 
the final study cohort (Figure 1). Of these 176 patients, the diagnosis of SAPH had been confirmed by 
RHC within one year of study entry in 84 cases (incident cases).  There was no significant difference 
between the hemodynamic features of the incident cases compared to the prevalent cases (Supplement 
Table 2).  All further analyses were performed on the combined group. Table 1 summarizes the 
demographic features of the total population. There were 81 (46.0%) cases with moderate to severe 
pulmonary hypertension 
16
 as defined by a mPAP>35 mm Hg.   
 
Figure 2A demonstrates the mPAP for the whole group. Figure 2B shows the PVR for the group.  There 
was no relationship between FVC % predicted or any other spirometric value and the pulmonary 
hemodynamics.  There was a significant correlation between DLCO % predicted and mPAP (Figure 3A, 
Rho=-0.228, p=0.0068) and PVR (Figure 3B, Rho=-0.362, p<0.0001). There was no correlation between 
FVC % predicted and either mPAP (Rho=0.0179, p>0.05) or PVR (Rho=0.126, p>0.05). 
 
The chest x-ray was staged using Scadding 
14
 criteria was available in 135 patients. Figure 4 
demonstrates the mPAP and PVR for the 89 patients with stage 4 chest x-ray versus the 46 with other 
stages. There was a significant difference between groups in regards to their PVR measurements 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
(Kruskal-Wallis test, p=0.034) with stage 4 patients having significantly higher values than either stage 0 
or 1 patients (p<0.05 for both comparisons) with no difference in mPAP.  
 
Based on WASOG criteria for organ involvement 
12
, patients were classified as either lung involvement 
only (80 patients) versus those with extra-pulmonary disease (96 patients). There was no significant 
difference in the mPAP pressure for those with lung only disease (36 (25-60) mm Hg) versus systemic 
disease (34 (25-62) mm Hg) or for PVR (lung only (5.44 (1.94, 18.3) Wood units) versus systemic disease 
(5.5 (1.85, 20.49) Wood units)).  
 
Of the 176 patients studied, 126 came from US centers and 50 from European or Middle Eastern 
centers. Table 2 describes the characteristics of the patients in both groups. There was no significant 
difference between groups in terms of age or gender. There were significant differences in the self-
declared race for the two groups (Chi Square=64.804, p<0.0001). For the reported hemodynamics, there 
was no difference in mPAP, but PVR was significantly higher for the non- US group (p=0.0079).  
 
There was no significant difference for spirometry or DLCO% predicted between the two groups. We 
compared those who were white versus black, regardless of country of origin. There was no difference 
in mPAP or PVR between the 57 white patients versus the 96 black patients (data not shown). There was 
also no difference in FVC or FEV1 % predicted between whites versus blacks (data not shown). However, 
white patients had a lower FEV1/FVC ratio (66 % (21-91), median [range]) than blacks (74% [27-91], 
p=0.0069). The DLCO% predicted was significantly lower for blacks (31% [3-69]) than whites (43.3% [14.2-
94], p=0.0020). 
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Table 1 also includes the results of 142 patients who underwent six minute walk testing at time of entry 
into the study.  The median 6MWD was 305 meters (range 11-610 meters). Most patients desaturated 
during the test, with a median degree of desaturation of 5%.  Figure 5 shows the distribution of the 
desaturation. A correlation between 6MWD and other features is summarized in Table 3. This univariate 
analysis identified six features with a p value of less than 0.05: end of walk Borg, sPAP, dPAP, mPAP, 
PVR, and DLCO% predicted. Multi-variate analysis of these six features detected three independent 
features: end of walk Borg (p=0.0014), sPAP (p=0.0047, and DLCO% predicted  (p=0.0002). There was a 
significant correlation between the DLCO% predicted and 6MWD (Figure 6: rho=0.380, p<0.0001).    
 
Table 4 compares the therapy at time of entry into the study for US versus non-US sites.  Nearly a third 
of US patients were not treated, while only four non-US patients were not on any therapy at time of 
entry into the registry (Chi square=11.26, p=0.0008). The US patients were more likely to be on current 
therapy with a calcium channel blocker than the non-US sites (Chi square 4.002, p=0.0454), but only 
seven were receiving a calcium channel blocker as monotherapy. There was no significant difference in 
endothelin receptor blockers or prostanoids usage.   The relatively low rate of usage of newer agents 
such as macitentan and riociguat probably reflects that most patients were started on therapy prior to 
the availability of these drugs.  
 
We compared the rate of treatment for mild versus moderate to severe pulmonary hypertension 
(mPAP>35 mm Hg). The results are summarized in Table 5. For the US sites, 55 of 126 (43.7%) had 
moderate to severe pulmonary hypertension versus 26 of 50 (52%) of the non-US sites (Chi 
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square=0.696, p>0.05). For both US and non-US sites, there was no significant difference in the rate of 
treatment for mild versus moderate to severe PH. When we compared the rate of treatment for US 
versus non-US sites, we still found a significant difference in rate of treatment for both mild and 
moderate to severe PH.   
 
Discussion 
 
Pulmonary hypertension is a recognized complication of sarcoidosis 
1;17;18
. However, there is still limited 
information regarding the clinical presentation and the role of therapy for this malady.  Because of the 
relatively low incidence, most reports are derived from single center experiences 
6;8
.  This current study 
prospectively obtained information on 176 RHC-confirmed cases of SAPH from the US, Europe, and the 
Middle East. This multinational approach provides a global perspective and insight into features of SAPH. 
It also identified regional differences, which were most apparent with regards to the implementation of 
treatment.  Half of the patients had been diagnosed with SAPH within a year of time of entry into the 
registry, however there was no significant difference between these incident cases and the remaining 
prevalent cases. Over 40% of our patients had moderate to severe PH.  
 
The current study was not designed to determine the prevalence of SAPH within any individual clinic. 
Previous reports from centers participating in the registry have found SAPH in over ten percent of all 
their patients 
6
. At another center, right heart catheterization was performed in sarcoidosis patients 
with persistent dyspnea 
1
. Over half of the patients studied had pulmonary hypertension, with a twenty 
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percent of those with pulmonary hypertension having left ventricular dysfunction. In referral centers, 
pulmonary hypertension has been identified in about ten percent of pulmonary sarcoidosis patients 
7;18
.  
 
It has been noted that SAPH patients have lower FVC and DLCO than other sarcoidosis patients 
5;7;8;18;19
.  
In our study, there was also a significant correlation between the DLCO% predicted and severity of PH 
(Figure 3). Overall, the median FVC was 60%, consistent with moderate restriction. There was no 
correlation between any of the spirometric values and severity of PH.  Several screening strategies have 
been proposed which include use of echocardiography, DLCO, 6MWD, and patient symptoms 
8;20;21. None 
of these were used in a systematic manner by the centers involved in this study.  An area for future 
studies is how these parameters can be used in concert to risk stratify for the presence and severity of 
PH.  
 
Previous studies have reported that the majority of SAPH patients have pulmonary fibrosis (Scadding 
stage 4) 
4;14
 based on chest x-ray changes.  While pulmonary fibrosis is a recognized cause of pulmonary 
hypertension, a significant proportion of cases have less advanced radiologic changes 
5;6;8;19,28
.  In the 
current study, half the patients had stage 4 chest x-ray findings. Figure 4 demonstrates that there was 
no significant difference in the mPAP for different Scadding stages, although the PVR was significantly 
higher for stage 4 compared to stage 0 or 1 SAPH patients.  Thus, our study suggests that presence of 
fibrosis is not essential for the development of SAPH and attests to the multifactorial nature of its 
etiology. One of the limitations of our study is that most patients were recruited from a tertiary 
sarcoidosis clinic and there may have led to patients with more advanced underlying lung disease. We 
also looked whether SAPH patients with extra-pulmonary disease had more severe pulmonary 
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hypertension. Although more than half of our patients had evidence of systemic disease, there was no 
difference in severity of SAPH for these patients compared to those with lung only disease. 
 
The 6MWD was reduced in our SAPH patients compared to other sarcoidosis patients 
22
.  A reduction in 
6MWD in SAPH patients has previously been reported 
22;23
.  Desaturation during the 6MWD test has 
been proposed as a method to identify patients with SAPH 
7
. There was a significant inverse correlation 
between 6MWD and mPAP as well as PVR (Table 3).  
 
Several drugs have been used to treat SAPH. These include prostenoids 
17;24
, endothelin receptor 
antagoinists 
25;26
, PDE-5 inhibitors 
27
, and combination therapy 
6;28
. Most SAPH patients were receiving 
PH-directed therapy at the time of entry into the study (Table 4). This is similar to the 77% of patients 
treated in the French registry 
4
.  At the time of enrollment, 84% of the non- US SAPH patients were 
receiving therapy for PH compared to 70% of the US patients.  In reviewing drug therapy for PH 70% of 
the non-US patients were receiving a PDE-5 inhibitor, while only 35% of the US patients were on a PDE-5 
inhibitor. The use of calcium channel blockers was significantly more common in the US sites. This may 
be a reflection of the previously noted overuse of channel blockers for pulmonary hypertension by US 
centers 
29
. A third of patients had vasoreactivity testing performed. However, the results of 
vasoreactivity testing were not predictive of which patients were subsequently treated with calcium 
channel blockers (data not shown). 
 
There are several possible reasons for the difference in rate of treatment of SAPH for US versus non-US 
sites. The rate of moderate to severe PH was similar for the US and non-US sites (Table 5). The rate of 
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treatment was significantly higher for non-US versus US sites for both the mild and moderate to severe 
PH patients. The current report only captured the treatment at time of entry into the study. Patients 
may have subsequently been started on therapy. Also, we were unable to determine whether the 
decision to not treat was because of lack of insurance coverage. The higher treatment rate for the non 
US sites may represent the efforts of the few specialized non US centers which participated in this study. 
However, the recent report from France 
4
 found that the overall rate of treating SAPH in France was 
higher than reported by our US centers. 
 
Conclusion 
This is the first study describing demographics and clinical features of a large multi-center international 
cohort of SAPH patients. There were few differences in the features of SAPH between the US and non-
US subjects. One should always consider pulmonary hypertension as a cause of persistent dyspnea in a 
sarcoidosis patient. SAPH patients in the US were less likely to be receiving treatment for their PH at the 
time of enrollment in the study. Hopefully, the registry will also foster a greater awareness of SAPH and 
encourage future randomized clinical trials to help define the role of therapy for this emerging entity.  
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Table 1 
Features of 176 patients with SAPH  
 
  SAPH 
  N  
Number  176 
Age  58 (34,81) * 
Female:Male   125:51 (71%:19%) † 
White/Black/Asian/Middle 
Eastern  
  57:96:5:19 (32%:55%:3%:11%) 
RA, mm Hg 165 5 (0,21) * 
sPAP, mm Hg 176 55 (35, 109) * 
dPAP, mm Hg 175 22 (7, 65) * 
mPAP, mm Hg 176 35 (25, 62) * 
PAWP, mm Hg 176 10 (1,15) * 
Cardiac Output 160 5.3 (2, 10.3) * 
Cardiac Index 130 2.82 (1.2, 5.04) * 
PVR 160 5.49 (1.85, 20.49) * 
FVC % predicted 168 60 (19, 132) * 
FEV1% predicted 169 54 (22, 119) * 
FEV1/FVC % 167 74 (21, 98) * 
DLCO % predicted 139 37 (13, 94) * 
Chest X-ray Scadding 
stage ‡ 
  
0 7 7 
1 4 4 
2 12 12 
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3 23 23 
4 89 89 
Six-minute walk test 
results * 
  
Distance walked (m) 142 305 (11,610) * 
End of walk Borg 142 4 (0,10) * 
End of walk oxygen 
saturation (%) 
142 90 (47, 100) * 
Change in saturation 
during walk 
142 -5 (-50, 10) * 
 
*Median (Range) 
†Number (percent) 
RAP - right atrial pressure; sPAP- systolic pulmonary artery pressure, dPAP – diastolic pulmonary artery 
pressure, mPAP - mean pulmonary artery pressure; PAWP – pulmonary artery wedge pressure; PVR – 
pulmonary vascular resistance; FVC – forced vital capacity; FEV1 – forced expiratory volume at 1 second; 
DLCO – diffusion capacity for carbon monoxide. 
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Table 2 
Characteristics of SAPH patients: US versus non-US clinics 
 US  Non US  
  N 
 
Median 
(range) 
N  Median (range) 
Number 126  50  
Age, years  58 (37,81)  56 (34,79) 
Female/Male 86/40 (68%;32%) *  39/11 (78%:22%)  
Race: 
White/Black/Asian/ 
Middle Eastern 
37/86/ 
4/0 (29%:68%: 3%: 
0%) 
 
20/10/1/19  
 (40%: 20%: 2%: 
38%)  
 
mPAP 126 34 (25,60) 50 36.5 (25, 62) 
Cardiac Index  109 
2.8 (1.2, 
5.04) 
21 3.01 (1.4, 4.13) 
PVR  115 
5.16 (1.85, 
18.32) 
45 
6.89 (1.97, 
20.49) † 
FVC % predicted 118 
58.5 
(19, 132) 
50 64.5 (28, 104) 
FEV1 % predicted 119 52 (22, 119) 50 56.9 (15.3, 91.7) 
FEV1/FVC % 119 
71 
(27, 91) 
48 79 (21, 98) 
DLCO % predicted 94 
37.25 
(3,94) 
45 36.3 (14.2,69) 
 mPAP - mean pulmonary artery; PVR -pulmonary vascular resistance; FVC – forced vital capacity; FEV1 – 
forced expiratory volume at 1 second; DLCO – diffusion capacity for carbon monoxide. 
*Number (percent) 
Differs from United States, Chi Square=64.804, p<0.0001 
†Differs from United States, p=0.0079 
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Table 3 
Correlation between six-minute walk distance and various parameters 
  Rho p 
Age -0.144 0.0874 
End of walk saturation -0.035 
0.687 
Change in oxygen 
saturation 
0.0788 
0.3617 
End of walk Borg -0.243 0.0054 
sPAP, mm Hg -0.281 0.007 
dPAP, mm Hg -0.176 0.0359 
mPAP mm Hg -0.196 0.0191 
PVR, Woods units -0.292 0.0008 
FVC% predicted 0.103 0.2261 
FEV1% predicted 0.09 0.2918 
DLCO% predicted 0.38 <0.0001 
Scadding stage -0.008 0.9376 
 
sPAP- systolic pulmonary artery, dPAP – diastolic pulmonary artery, mPAP - mean pulmonary artery 
mean; PVR _ pulmonary vascular resistance; FVC – forced vital capacity; FEV1 – forced expiratory volume 
at 1 second; DLCO – diffusion capacity for carbon monoxide. 
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Table 4 
Therapy at time of entry into registry 
 
  US non US 
Number of Patients 126 50 
  Current Current 
Epoprostenol 3 (2%)  § 0 
Treprostinil * 7 (6%) 0 
Iloprost 1 (1%) 1 (2%) 
Any prostacyclin  11 (9%) 1 (2%)   
Ambrisentan 16 (13%) 3 (6%) 
Bosentan 20 (16%) 13 (26%) 
Macitentan 4 (3%) 2 (4%) 
Any ERA 40 (32%) 18 (36%) 
Sildenafil 28 (22%) 35 (70%) 
Tadalafil 19 (15%) 0 
Any PDE-5 inhibitor  44 (35%) 35 (70%) 
Riociguat 1 (1%) 0 
      
Any calcium channel 
blocker † 
21 (16.7%) 2 (4%) 
      
No therapy ** 41 (32.5%) 4 (2%) 
 
 
*No patient previously on epoprostenol 
§Number (percent of total for group US or non-US) 
 Chi square=17.704, p<0.0001. 
† Chi square=4.002, p=0.0454 
** Chi square=11.26, p=0.0008  
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Table 5 
Comparison of treatment for US and non-US patients with mild versus moderate-severe pulmonary 
hypertension * 
 
  
Mild Pulmonary 
Hypertension PA 
mean< 35 mm 
HG     
Moderate-
severe 
Pulmonary 
Hypertension 
PA mean> 35 
mm Hg   
  Total number 
No 
Therapy 
 
Total Number No Therapy 
US  71 26 (37%) 
 
55 15 (27%) 
non US 24 3 (12%) * 
 
26 1 (4%)  
 
*Differs from US, Chi square=3.849, p=0.0498. 
Differs from US, Chi square=4.724, p=0.0297. 
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Figure Legend 
 
Figure 1 Flow sheet of 216 patients in the sarcoidosis associated pulmonary arterial hypertension 
registry. Based on right heart catheterization measurements, 176 patients were 
identified with a pulmonary artery mean (mPAP) > 25 mm Hg and a pulmonary capillary 
wedge (PAWP) of 15 mm Hg or less.  
Figure 2 Histogram of mPAP (Figure 2A) and PVR (Figure 2B) for the whole population. 
Figure 3 Comparison between DLCO percent predicted and mPAP (Figure 3A, Rho=-0.228, 
p=0.0068) and PVR (Figure 3B, Rho=-0.362, p<0.0001). 
Figure 4 Comparison between the Scadding 
14
 chest x-ray stage and the mPAP (Figure 4A) and 
PVR (Figure 4B). There was no difference between groups for mPAP. There was a 
significant difference between PVR for different chest x-ray patterns (Kruskal-Wallis, 
p=0.033507), with stage 4 being significantly different from those who were stage 0 or 1 
(p<0.05 for both comparisons). 
Figure 5 Relative frequency of oxygen desaturation detected by oximetry during six minute walk 
of 142 patients. 
Figure 6 Correlation between DLCO percent predicted and 6 minute walk distance (rho=0.380, 
p<0.0001).   
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Highlights 
• Multi-national study of 176 sarcoidosis associated pulmonary hypertension patients 
• Similar clinical features across US, Europe, and Middle East 
• Pulmonary vascular resistance was higher in patients with pulmonary fibrosis 
• There was a correlation between DLCO and level of pulmonary hypertension 
• Pulmonary hypertension was more likely to be treated in Europe than US 
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